<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcwomenshealth&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Women&apos;s Health - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcwomenshealth/</link>
        <description>The latest research articles published by BMC Women&apos;s Health</description>
        <dc:date>2009-07-01T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/19" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/18" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/17" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/16" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/15" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/14" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/13" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/12" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/11" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/9/10" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/19">
        <title>Effects of multiparity and prolonged breast-feeding on maternal bone mineral density: a community-based cross-sectional study </title>
        <description>Background:
Studies conducted in Western countries have shown that bone loss associated with pregnancy and breast-feeding is recovered after weaning. However, it is not clear whether recovery takes place after repeated pregnancies followed by prolonged periods of breast-feeding; especially in developing countries where nutritional intake is comparatively low.This study was designed to examine the effects of multiparity and prolonged breast-feeding on maternal bone mineral density (BMD) in a community-based sample of 210 Sri Lankan women, aged between 46 and 98 years.
Methods:
BMD of the lumbar spine (L2-L4) and femoral neck were measured by dual-energy X-ray absorptiometry. Reproductive history was recorded by using a questionnaire. Women were, first, divided into groups according to parity (nulliparous, 1-2, 3-4, and 5 or more children), and BMDs in different groups were compared, initially unadjusted and then adjusted for age. Same subjects were subdivided, again, according to the total duration of breast-feeding (0, 1-48, 49-96, and 97 months or more) and similar analysis was carried out.
Results:
Women who had 5 or more children and women who had breast-fed for 97 months or more were older than the other women (p&lt;0.01) but no differences in height, weight or BMI were observed among the groups. Age adjusted BMD at lumbar spine and femoral neck of the women grouped according to parity were not significantly different. Neither was there any difference between lumbar spine or femoral neck age adjusted BMDs in groups based on duration of breast-feeding.
Conclusions:
From this population-based study conducted in a developing country, we infer that history of multiparity or prolonged breast-feeding has no detrimental effects on maternal BMD in post-menopausal age.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/19</link>
                <dc:creator>Janaka Lenora</dc:creator>
                <dc:creator>Sarath Lekamwasam</dc:creator>
                <dc:creator>Magnus Karlsson</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:19</dc:source>
        <dc:date>2009-07-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-19</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2009-07-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/18">
        <title>Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women&apos;s experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy </title>
        <description>Background:
For many women finding the right contraceptive method can be challenging and consistent and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be a challenge. The primary objective of this study was to evaluate women&apos;s experience with a weekly ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently developed in hormonal contraception to increase women&apos;s options in avoiding daily dosing.
Methods:
In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end, overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated.
Results:
175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied. Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred the patch, for convenience (53.9%), ease of use/simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and the mean subject&apos;s compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe and well tolerated: adverse events frequency was low, with predominantly single reports of each event. Most of them started and subsided during cycle 1.
Conclusions:
This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels and excellent compliance. At study end, the majority of women indicated that they would continue using the patch.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/18</link>
                <dc:creator>Pier Giorgio Crosignani</dc:creator>
                <dc:creator>Carmine Nappi</dc:creator>
                <dc:creator>Salvatore Ronsini</dc:creator>
                <dc:creator>Vincenzina Bruni</dc:creator>
                <dc:creator>Silvia Marelli</dc:creator>
                <dc:creator>Davide Sonnino</dc:creator>
                <dc:creator>Italian EVRA Contrast Study Group</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:18</dc:source>
        <dc:date>2009-06-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-18</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2009-06-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/17">
        <title>Effect of 6-months of physical exercise on the nitrate/nitrite levels in hypertensive postmenopausal women</title>
        <description>Background:
Evidences have shown that the incidence of arterial hypertension is greater in postmenopausal women as compared to premenopausal. Physical inactivity has been implicated as a major contributor to weight gain and abdominal obesity in postmenopausal women and the incidence of cardiovascular disease increases dramatically after menopause. Additionally, more women than men die each year of coronary heart disease and are twice as likely as men to die within the first year after a heart attack. A healthy lifestyle has been strongly associated with the regular physical activity and evidences have shown that physically active subjects have more longevity with reduction of morbidity and mortality. Nitric oxide (NO) produced by endothelial cells has been implicated in this beneficial effect with improvement of vascular relaxing and reduction in blood pressure in both laboratory animals and human. Although the effect of exercise training in the human cardiovascular system has been largely studied, the majority of these studies were predominantly conducted in men or young volunteers. Therefore, the aim of this work was to investigate the effects of 6 months of dynamic exercise training (ET) on blood pressure and plasma nitrate/nitrite concentration (NOx-) in hypertensive postmenopausal women.
Methods:
Eleven volunteers were submitted to the ET consisting in 3 days a week, each session of 60 minutes during 6 months at moderate intensity (50% of heart rate reserve). Anthropometric parameters, blood pressure, NOx- concentration were measured at initial time and after ET.
Results:
A significant reduction in both systolic and diastolic blood pressure values was seen after ET which was accompanied by a marked increase of NOx- levels (basal: 10 +/- 0.9; ET: 16 +/- 2 muM). Total cholesterol was significantly reduced (basal: 220 +/- 38 and ET: 178 +/- 22 mg/dl), whereas triglycerides levels were not modified after ET (basal: 141 +/- 89 and ET: 147 +/- 8 mg/dl).
Conclusions:
Our study shows that changing in lifestyle promotes reduction of arterial pressure which was accompanied by increase in nitrite/nitrate concentration. Therefore, 6-months of exercise training are an important approach in management arterial hypertension and play a protective effect in postmenopausal women.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/17</link>
                <dc:creator>Pedro Zaros</dc:creator>
                <dc:creator>Carla Romero Pires</dc:creator>
                <dc:creator>Mauricio Bacci</dc:creator>
                <dc:creator>Camila Moraes</dc:creator>
                <dc:creator>Angelina Zanesco</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:17</dc:source>
        <dc:date>2009-06-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-17</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2009-06-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/16">
        <title>The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial</title>
        <description>Background:
With the exception of sexual functioning and weight, social and behavioural effects of postmenopausal hormone therapy (HT) have not been reported from trials. This paper reports such results from the EPHT-trial in Estonia.
Methods:
A randomized trial, with a blind and non-blind sub-trial in Estonia. From 1999&#8211;2001, 1778 women were recruited. The mean follow-up was 3.6 years. Women&apos;s experiences were asked in the first and final study year by mailed questionnaires (74 and 81% response rates). Comparisons of the groups were made by cross-tabulation and logistic regression, adjusting for age.
Results:
There were no differences between the HT and non-HT groups in regard to being employed, the extent of social involvement or marital status or opinions on aging. There was no difference in the frequency of free-time exercise, or overweight. Some of the indicators suggested less sexual inactivity, but the differences were small.
Conclusion:
In a trial setting, postmenopausal hormone therapy did not influence work or social involvement or health behaviour.Trial registrationISRCTN35338757</description>
        <link>http://www.biomedcentral.com/1472-6874/9/16</link>
                <dc:creator>Elina Hemminki</dc:creator>
                <dc:creator>Piret Veerus</dc:creator>
                <dc:creator>Heti Pisarev</dc:creator>
                <dc:creator>Sirpa-Liisa Hovi</dc:creator>
                <dc:creator>Paivi Topo</dc:creator>
                <dc:creator>Helle Karro</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:16</dc:source>
        <dc:date>2009-06-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-16</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2009-06-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/15">
        <title>Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial</title>
        <description>Background:
Premature menopause is a major concern of younger women undergoing adjuvant therapy for breast cancer. Hormone replacement therapy is contraindicated in women with a history of breast cancer. Non-hormonal medications show a range of bothersome side-effects. There is growing evidence that cognitive behavioral therapy (CBT) and physical exercise can have a positive impact on symptoms in naturally occurring menopause. The objective of this study is to investigate the efficacy of these interventions among women with breast cancer experiencing treatment-induced menopause.Methods/designIn a randomized, controlled, multicenter trial, we are evaluating the effectiveness of CBT/relaxation, of physical exercise and of these two program elements combined, in reducing menopausal symptoms, improving sexual functioning, reducing emotional distress, and in improving the health-related quality of life of younger breast cancer patients who experience treatment-induced menopause. 325 breast cancer patients (aged &lt; 50) are being recruited from hospitals in the Amsterdam region, and randomly allocated to one of the three treatment groups or a &apos;waiting list&apos; control group. Self-administered questionnaires are completed by the patients at baseline, and at 12 weeks (T1) and 6 months (T2) post-study entry. Upon completion of the study, women assigned to the control group will be given the choice of undergoing either the CBT or physical exercise program.DiscussionCognitive behavioral therapy and physical exercise are potentially useful treatments among women with breast cancer undergoing treatment-induced, premature menopause. For these patients, hormonal and non-hormonal therapies are contraindicated or have a range of bothersome side-effects. Hence, research into these interventions is needed, before dissemination and implementation in the current health care system can take place.Trial registrationThe study is registered at the Netherlands Trial Register (NTR1165) and ClinicalTrials.gov (NCT00582244).</description>
        <link>http://www.biomedcentral.com/1472-6874/9/15</link>
                <dc:creator>Saskia Duijts</dc:creator>
                <dc:creator>Hester Oldenburg</dc:creator>
                <dc:creator>Marc van Beurden</dc:creator>
                <dc:creator>Neil Aaronson</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:15</dc:source>
        <dc:date>2009-06-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-15</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2009-06-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/14">
        <title>Informing women about hormone replacement therapy:
the Consensus conference statement</title>
        <description>Background:
The risks/benefits balance of hormone replacement therapy is controversial. Information can influence consumers&apos; knowledge and behavior; research findings about hormone replacement therapy are uncertain and the messages provided by the media are of poor quality and incomplete, preventing a fully informed decision making process.We therefore felt that an explicit, rigorous and structured assessment of the information needs on this issue was urgent and we opted for the organisation of a national consensus conference (CC) to assess the current status of the quality of information on hormone replacement therapy (HRT) and re-visit recent research findings on its risks/benefits.
Methods:
We chose a structured approach based on the traditional CC method combined with a structured preparatory work supervised by an organising committee (OC) and a scientific board (SB). The OC and SB chose the members of the CC&apos;s jury and appointed three multidisciplinary working groups (MWG) which were asked to review clinical issues and different aspects of the quality of information. Before the CC, the three MWGs carried out: a literature review on the risk/benefit profile of HRT and two surveys on the quality of information on lay press and booklets targeted to women. A population survey on women&apos;s knowledge, attitude and practice was also carried out. The jury received the documents in advance, listened the presentations during the two-day meeting of the CCs, met immediately after in a closed-door meeting and prepared the final document. Participants were researchers, clinicians, journalists as well as consumers&apos; representatives.
Results:
Key messages in the CC&apos;s deliberation were: a) women need to be fully informed about the transient nature of menopausal symptoms, about HRT risks and benefits and about the availability of non-pharmacological interventions; b) HRT is not recommended to prevent menopausal symptoms; c) the term &quot;HRT&quot; is misleading and &quot;post menopausal hormone therapy&quot; should be the preferred definition.
Conclusion:
This CC led to the identification of specific information drawbacks. Women are exposed to messages that are often partial, non evidence-based nor transparently developed. The structured and participative methodology of this CC allowed a multidisciplinary perspective and a substantial lay people input.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/14</link>
                <dc:creator>Paola Mosconi</dc:creator>
                <dc:creator>Serena Donati</dc:creator>
                <dc:creator>Cinzia Colombo</dc:creator>
                <dc:creator>Alfonso Mele</dc:creator>
                <dc:creator>Alessandro Liberati</dc:creator>
                <dc:creator>Roberto Satolli</dc:creator>
                <dc:creator>on behalf of Consensus Conference Working Group</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:14</dc:source>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-14</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2009-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/13">
        <title>Hot flushes and quality of life during menopause </title>
        <description>Menopausal health is important since this stage of life is not to be avoided. A recent article in BMC Women&apos;s Health from the Estonian Postmenopausal Hormone Therapy trial has concluded that quality of life is not related to hormonal therapy use. The commentary article discusses this finding and considers other factors related to symptoms and quality of life during menopause. Important factors known to affect hot flushes and quality of life are smoking and high body weight. Since both these factors are modifiable, menopause is a suitable area for health promotion. However, evidence concerning lifestyle changes in symptom relief or increase of quality of life is weak. More trials in this area are needed before women may consider non-pharmacological treatment of symptoms as a reliable option for menopausal symptom cure.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/13</link>
                <dc:creator>Riitta Luoto</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:13</dc:source>
        <dc:date>2009-05-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-13</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2009-05-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/12">
        <title>Clients&apos; reason for prenatal ultrasonography in Ibadan, South West of Nigeria.</title>
        <description>Background:
Prenatal ultrasonography has remained a universal tool but little is known especially from developing countries on clients&apos; reasons for desiring it. Then aim was to determine the reasons why pregnant women will desire a prenatal ultrasound.
Methods:
It was a cross-sectional survey of consecutive 222 women at 2 different ultrasonography facilities in Ibadan, South-west Nigeria.
Results:
The mean age of the respondents was 30.1 &#177; 4.5 years. The commonest reason for requesting for prenatal ultrasound scans was to check for fetal viability in 144 women (64.7%) of the respondents, followed by fetal gender determination in 50 women (22.6%. Other reasons were to check for number of fetuses, fetal age and placental location. Factors such as younger age, artisans profession and low level of education significantly influenced the decision to check for fetal viability on bivariate analysis but all were not significant on multivariate analysis. Concerning fetal gender determination, older age, Christianity, occupation and gravidity were significant on bivariate analysis, however, only gravidity and occupation remained significant independent predictor on logistic regression model. Women with less than 3 previous pregnancies were about 4 times more likely to request for fetal sex determination than women with more than 3 previous pregnancies, (OR 3.8 95%CI 1.52 &#8211; 9.44). The professionals were 7 times more likely than the artisans to request to find out about their fetal sex, (OR 7.0 95%CI 1.47 &#8211; 333.20).
Conclusion:
This study shows that Nigerian pregnant women desired prenatal ultrasonography mostly for fetal viability, followed by fetal gender determination. These preferences were influenced by their biosocial variables.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/12</link>
                <dc:creator>Christopher Enakpene</dc:creator>
                <dc:creator>Imran Morhason-Bello</dc:creator>
                <dc:creator>Anthony Marinho</dc:creator>
                <dc:creator>Babatunde Adedokun</dc:creator>
                <dc:creator>Adegoke Kalejaiye</dc:creator>
                <dc:creator>Kayode Sogo</dc:creator>
                <dc:creator>Sikiru Gbadamosi</dc:creator>
                <dc:creator>Babatunde Awoyinka</dc:creator>
                <dc:creator>Obehi Enabor</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:12</dc:source>
        <dc:date>2009-05-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-12</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-05-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/11">
        <title>Satisfaction and quality of life in women who undergo breast surgery: a qualitative study
</title>
        <description>Background:
In cosmetic and reconstructive breast surgery, measurement of patient-reported outcomes has become increasingly important to research efforts and clinical care. We aimed to describe how breast conditions and breast surgery impact on patient satisfaction and quality of life.
Methods:
We conducted qualitative, in-depth interviews with 48 women who had undergone either breast reduction (n = 15), breast augmentation (n = 12), or breast reconstruction (n = 21) surgery in order to begin to build a theoretical understanding of patient satisfaction and quality of life in breast surgery patients. Interviews were audio-taped, transcribed verbatim and analyzed thematically.
Results:
The patient interviews revealed that breast conditions and breast surgery impact women in the following six main areas: satisfaction with breasts; satisfaction with overall outcome; psychosocial well-being; sexual well-being; physical well-being; and satisfaction with the process of care. We used these six themes to form the basis of a conceptual framework of patient satisfaction and quality of life in women who undergo breast surgery.
Conclusion:
Our conceptual framework establishes the main issues of concern for breast surgery patients. This new framework can be used to help develop local guidelines for future clinical assessment, management and measurement, establish the validity of the current management strategies, and develop evidence-based guidance for the development of new patient reported outcome measures for future outcomes research.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/11</link>
                <dc:creator>Anne Klassen</dc:creator>
                <dc:creator>Andrea Pusic</dc:creator>
                <dc:creator>Amie Scott</dc:creator>
                <dc:creator>Jennifer Klok</dc:creator>
                <dc:creator>Stefan Cano</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:11</dc:source>
        <dc:date>2009-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-11</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/9/10">
        <title>Dietary fat intake and gestational weight gain in relation to estradiol and progesterone plasma levels during pregnancy: a longitudinal study in Swedish women</title>
        <description>Background:
Elevated pregnancy hormone levels, such as oestrogen and progesterone, may increase the risk of developing breast cancer both in mothers and offspring. However, the reasons for large inter-individual variations in estrogen and progesterone levels during pregnancy remain unknown. The objectives of this study were to investigate whether a) intakes of total dietary fat, types of fat (monounsaturated: MUFA, polyunsaturated: n-3 and n-6 PUFA, and saturated) and b) gestational weight gain are associated with estradiol and progesterone levels in plasma during pregnancy.
Methods:
We measured body weight as well as estradiol and progesterone in plasma among 226 healthy pregnant Swedish women on gestation weeks 12, 25 and 33. At the same time points, dietary intake of total fat and types of fat (MUFA, PUFA, SFA, n-3 and n-6 PUFA) were estimated using 3-day food diaries.
Results:
A large variation in estradiol and progesterone levels was evident.Nulliparous women had 37%, 12% and 30% higher mean estradiol levels on gestation weeks 12, 25 and 33 compared to parous women (P = 0.008). No associations were found between dietary intake of total fat or fat subtypes (including n-3 PUFA and n-6 PUFA) and plasma estradiol or progesterone levels. Gestational weight gain was associated with progesterone levels (P = 0.03) but the effect was very small (20% increase in progesterone levels between gestational weeks 12 and 33 per kg body weight/week).
Conclusion:
No associations among gestational weight gain, maternal dietary fat intake (total or subtypes including n-3 PUFA and n-6 PUFA) and plasma estradiol levels were found. However, pregnancy progesterone levels correlated with weight gain during pregnancy. Identification of other possible determinants of pregnancy estradiol and progesterone levels, important for the development of breast cancer in both mothers and offspring, are needed.</description>
        <link>http://www.biomedcentral.com/1472-6874/9/10</link>
                <dc:creator>Marie Lof</dc:creator>
                <dc:creator>Leena Hilakivi-Clarke</dc:creator>
                <dc:creator>Sven Sandin</dc:creator>
                <dc:creator>Sonia de Assis</dc:creator>
                <dc:creator>Wei Yu</dc:creator>
                <dc:creator>Elisabete Weiderpass</dc:creator>
                <dc:source>BMC Women&apos;s Health 2009, 9:10</dc:source>
        <dc:date>2009-04-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-9-10</dc:identifier>
        <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-04-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
